Impaired mitochondrial adaptation can compromise matrix homeostasis, inflammatory resolution, mechanobiological signaling, and repair-cell function

The gap

Evidence profile

Sourced from the future work and stated challenges of the source papers, classified as general, drawn from work published between 2025 and 2026, spanning 6 journals. Those papers have been cited 21 times in total.

Supporting evidence — 7 representative gaps

• Mitochondrial translational control in cardiovascular diseases: from mechanisms to therapies (2026) · Redox Biology · doi

  Mitochondrial translation extends far beyond basic cellular house- keeping. In the highly oxidative myocardium, it operates as the ultimate checkpoint linking genomic output directly to metabolic demand. This precision relies entirely on the physical architecture of the IMM, where protein synthesis, complex assembly, and bioenergetics inherently intersect. However, a shared pathology connects I/R injury, HF, and inherited cardiomyopathies: the gradual loss of both physical coupling and functional coordination between mitochondrial translation, mem- brane insertion, and OXPHOS assembly. At the molecular level, this uncoupling initiates a severe proteotoxic cycle. Membrane depolarization directly stalls peptide elongation, while the simultaneous collapse of scaffolding complexes like MICOS and MITRAC leaves highly hydrophobic nascent subunits orphaned and prone to aggregation [34,81,110]. Concurrent redox stress, metabolic starvation, and epigenetic RNA modifications further suppress ribo- somal output. The temporal regulation of this decline remains highly context dependent. Acute insults like ischemia primarily disrupt early initiation events, whereas chronic failure often involves sustained epi- transcriptomic reprogramming through altered tRNA modifications and accelerated ribosome degradation. Ultimately, translational arrest evolves from a temporary protective pause into a primary source of widespread structural damage, driving cristae loss and triggering ter- minal quality control pathways. Identifying the exact molecular threshold where this adaptation becomes permanent dysfunction will dictate the success of future interventions. Because translational collapse actively drives pathology, rescuing this machinery offers a highly specific therapeutic angle. Instead of broadly stimulating cellular metabolism, newer approaches aim to resolve targeted translational bottlenecks. Compounds like SS-31 demonstrate the value of stabilizing the local lipid environment to ensure successful cotranslational membrane insertion [148,197]. Future drug design must move toward even greater precision, isolating specific initiation factors, epitranscriptomic enzymes, or structural assembly platforms. Concurrently, breakthrough genetic tools like base editors and organelle transplantation present opportunities to address root causes by permanently correcting or replacing defective genomic tem- plates [164,168]. To apply these tools effectively, the field urgently requires sensitive liquid biopsies capable of detecting circulating 13 Y. Deng et al. Redox Biology 92 (2026) 104143 ribosomal fragments or tRNA derivatives, allowing clinicians to stratify patients based on their specific translational defects. Future research must move beyond static measurements and actively track the dynamic real time progression of mitochondrial RNA pro- cessing, epitranscriptomics, and ribosome assembly. High resolution spatial and multi-omic profiling will be vital for mapping the exact in vivo trajectory of translational decline. Ultimately, cardiovascular medicine must pivot from simply managing late stage energy deficits toward proactively preserving the molecular machinery that builds the respiratory chain. By safeguarding the delicate interface between pro- tein synthesis and structural assembly, stabilizing mitochondrial trans- lation stands out as a foundational strategy for long term cardiac repair. CRediT authorship contribution statement Yunong Deng: Investigation, Visualization, Writing – original draft. Ningning Guo: Funding acquisition, Investigation, Visualization, Writing – original draft, Writing – review & editing. Die Li: Investiga- tion, Writing – original draft. Zhihua Wang: Conceptualization, Fund- ing acquisition, Project administration, Resources, Supervision, Writing – review & editing.

  generalfuture work
  Keywords: assembly translational writing mitochondrial highly like molecular structural future specific must original draft translation beyond
• Echoes in the powerhouse: mito-lncRNAs contribution to cardiac function and disease (2026) · Acta Pharmacologica Sinica · doi

  Mito-lncRNAs have emerged as key regulators of cardiac influencing bioenergetics, oxidative mitochondrial homeostasis, stress responses, calcium handling, and mitochondrial quality control. Dysregulation of molecules such as LIPCAR, MALAT1, RMRP, H19, and lncND5 has been linked to AMI, heart failure, Acta Pharmacologica Sinica (2026) 0:1 – 17 cardiomyopathy, and pulmonary hypertension [37, 41, 55, 88, 90]. Several of these transcripts demonstrate promising diagnostic and prognostic performance in early clinical studies. Preclinical models further suggest that correcting disease-associated mitochondrial lncRNA imbalances can partially restore mitochondrial function these findings and attenuate cardiac dysfunction. Together, position mito-lncRNAs as mechanistically informative candidates therapeutic for biomarker development modulation. and, potentially, compartment-specific mechanisms, However, the field remains in an early translational stage, and key challenges must be addressed systematically. Methodological limita- tions in defining true mitochondrial localization, an incomplete limited of understanding sequence conservation across species, and inefficient delivery to the heart and mitochondria remain major barriers. To address these challenges, future work should explicitly link each challenge to targeted experimental strategies. Detection and localization issues will require orthogonal validation, including rigorously controlled mito- chondrial fractionation, high-resolution RNA imaging, and emerging single-cell and spatial transcriptomic approaches. These methods help distinguish genuine mitochondrial signals from nuclear or cytoplasmic ones. Mechanistic ambiguity should be addressed with compartment- restricted gene-editing or silencing tools, RNA–protein interactome mapping, and structure–function analyses to identify the domains and interactions that drive mitochondrial phenotypes. To improve translational relevance, greater emphasis should be placed on human iPSC-derived cardiomyocytes, engineered cardiac tissues, organoids, and humanized or large-animal models that better capture human- specific lncRNA regulation. On the therapeutic front, progress will depend on developing cardiotropic and mitochondria-directed RNA delivery platforms—such as optimized viral vectors, lipid-based systems, or RNA constructs incorporating targeting motifs—alongside standardized frameworks for assessing biodistribution, immunogeni- city, and long-term safety. For biomarker translation, large, multi- center, and ethnically diverse prospective studies with harmonized assay protocols will be essential to determine whether mito-lncRNA signatures provide robust, incremental value over existing clinical these methodological and translational challenges are tools. addressed in a coordinated manner, mito-lncRNAs have the potential to contribute meaningfully to more precise risk stratification and to targeted modulation of mitochondrial dysfunction in cardiovascular disease.

  generalfuture work
  Keywords: mitochondrial mito lncrnas cardiac lncrna translational challenges addressed heart early clinical models disease function dysfunction
• Mitochondria in health and disease: cellular powerhouses, signaling centers, and drivers of dysfunction (2026) · Frontiers in Cell and Developmental Biology · doi

  Mitochondria have evolved far beyond their familial role as ATP generators. These organelles function as cellular centres that integrate energy metabolism, calcium homeostasis, redox signalling, and programmed cell death. Their dynamic nature, manifested via coordinated series of biogenesis, fusion, fission, and mitophagy, enables precise adaptation to physiological demands across diverse tissues. Consequently, mitochondrial integrity is essential to cellular and organismal health. Mitochondrial dysfunction, arising from bioenergetic failure, genetic mutations, or oxidative stress, is implicated in several pathologies, such as metabolic syndrome, neurodegenerative reproductive dysfunction, disorders, cardiovascular disease, cancer, and ageing. This review has systematically highlighted the molecular mechanisms of mitochondrial function and dysfunction, linking mitochondrial impairment to disease pathogenesis and exploring emerging therapeutic strategies. The therapeutic landscape has expanded considerably. Targeted antioxidants (MitoQ, SkQ1) neutralise pathological ROS at their source; PGC-1α activators and NAD+ precursors rejuvenate mitochondrial networks; gene-editing technologies (mitoTALENs, mtZFNs) offer potential to eliminate pathogenic mtDNA mutations; and mitochondrial transplantation represents a paradigm-shifting approach to organelle replacement. Yet clinical translation is limited. The failure of MitoQ in Phase II trials for Parkinson’s disease, hepatitis C, and ALS underscores the gap between preclinical promise and clinical reality, highlighting inadequate BBB penetration, lack of robust biomarkers, and failure to address upstream bioenergetic defects rather than downstream ROS. Future research must prioritize overcoming delivery barriers, especially the blood–brain barrier, through receptor-mediated transcytosis, extracellular vesicles, and focused ultrasound. Tissue-specific targeting using engineered lipid nanoparticles and is vital. Regulatory challenges, mitochondriotropic peptides including the lack of validated surrogate endpoints, disease heterogeneity, and evolving frameworks for gene-editing and mitochondrial replacement, need collaborative regulatory science and adaptive trial designs. Ethical considerations surrounding germline modification, identity, equity, and informed consent require engagement. Improved preclinical models, including patient-derived iPSCs and therapies addressing multiple organoids, and combination pathogenic mechanisms simultaneously, are critical for successful translation. The future of mitochondrial medicine does not lie in a single “magic bullet” but in the integration of sophisticated delivery science, rigorous regulation, thoughtful ethics, and interdisciplinary collaboration, symptomatic management to restoration of mitochondrial health. and public transitioning transparent governance eventually from

  generalfuture work
  Keywords: mitochondrial disease dysfunction failure function cellular health bioenergetic mutations mechanisms therapeutic mitoq gene editing pathogenic
• Mitochondrial dysfunction in sepsis: nutritional strategies for restoring bioenergetic homeostasis (2026) · Frontiers in Cellular and Infection Microbiology · doi

  A critical priority for future research is the translation of mechanistically promising preclinical findings into clinically vali- dated interventions. While the evidence for PDC impairment, mtROS-driven inflammasome activation, and mitophagy failure is well-established in animal models and cell-based systems, human data remain sparse and largely observational. Few randomized controlled trials have tested thiamine, carnitine, or CoQ10 with robust mitochondrial endpoints, and those that exist are limited by small sample sizes, heterogeneous populations, and variable timing of intervention. Moving forward, trials must be designed with prespecified mitochondrial biomarkers—such as whole-blood thia- mine levels, plasma acetylcarnitine profiles, or circulating mtDNA —to identify patients most likely to benefit, and should incorporate direct measures of mitochondrial function (e.g., oxygen consump- tion, membrane potential, or ATP synthesis) as secondary or exploratory endpoints. Additionally, the optimal timing, dosing, and combination strategies for these nutrients remain undefined; preclinical studies suggest that early intervention before irreversible organ damage occurs is critical, but this has not been systematically tested in humans. Addressing these gaps will require multicenter, biomarker-stratified trials that evaluate not only survival but also organ function recovery, mitochondrial bioenergetic restoration, and long-term functional outcomes. A second priority is biomarker development. The field needs robust, clinically feasible indicators that can define mitochondrial injury in real time, stratify patients by bioenergetic vulnerability and monitor treatment response. For thiamine specifically, future trials should incorporate baseline thiamine level measurement and re- strict enrollment to deficient patients, as the signal for mortality benefit has only appeared in this subgroup to date. Such markers must move beyond nonspecific inflammatory or metabolic readouts and capture the functional state of mitochondrial substrate use, oxidative stress and quality control. Without this layer of precision, nutrient-based mitochondrial therapy will remain conceptually attractive but operationally imprecise. Translational studies must also become more mechanistically disciplined. Future clinical trials should not test thiamine, carnitine, or coenzyme Q10 as broadly interchangeable adjuncts. They should be designed around a clear metabolic hypothesis, a defined septic phenotype and biologically relevant endpoints. This will be espe- cially important for determining optimal timing, dosing and com- bination strategies. The most informative next-generation trials will likely be those that match intervention to mitochondrial lesion rather than evaluating nutritional molecules in unselected septic populations. For thiamine, we consider whole blood or plasma thiamine level the most clinically ready biomarker, as patients with documented deficiency consistently derive grea

  generalfuture work
  Keywords: mitochondrial trials thiamine patients future clinically remain endpoints timing intervention must biomarker critical priority mechanistically
• Mitochondrial structural and functional aberrations in diabetic bladder dysfunction: underlying mechanisms and therapeutic landscapes (2026) · Acta Diabetologica · doi

  While mitochondrial dysfunction undeniably sits at the pathophysiological epicenter of DBD, the current research landscape remains disproportionately fixated on interrogat- ing isolated pathways, glaringly lacking a holistic appre- ciation of the intricate coupling networks among oxidative stress, energetic collapse, and MQC. These mechanisms operate not as secluded silos, but dynamically interact to weave a highly integrated mitochondrial regulatory web, collectively dictating the cell's energetic fate and ultimate survival. However, the spatiotemporal signatures of this network across varied cellular lineages and pathological milestones remain largely uncharted; crucially, identify- ing whether a unifying, pan-mitochondrial signaling axis exists that mechanistically tethers ROS genesis and ATP 1 3Acta Diabetologica Fig. 2 Mitochondria-targeted therapeutic architectures for DBD exhaustion to irreversible cellular damage persists as an urgent, unresolved scientific mandate. Confronting this complexity, therapeutic arsenals against DBD must urgently pivot from empirical symptomatic relief toward mechanism-driven, precision engineering. Although contemporary mitochondria-targeted antioxidants, meta- bolic modulators, and MQC interventions flash immense latent promise, their collective status remains largely teth- ered to proof-of-concept stages, with clinical translatability severely hamstrung by sub-optimal targeting fidelity and unidimensional scopes of action. Future paradigms must pivot toward constructing individualized interventional algorithms informed by mechanistic stratification, deploy- ing multi-target combinatorial strategies that seamlessly integrate redox homeostasis, bioenergetic flux, and mito- chondrial dynamics to orchestrate a systemic architectural rebuild of cellular function. Meanwhile, cell-free modali- ties like mitochondrial transplantation require rigorous vali- dation of delivery safety, and future trials should stratify patients by biomarkers to separate guideline-based adjuncts from purely experimental interventions. While mitochon- dria- instructed regenerative modalities mint a revolution- ary interventional framework for DBD, their mechanistic specificity and long-term biological safety mandate rigorous forthcoming validation. Ultimately, catalyzing the profound integration of deep mechanistic mitochondrial insights with highly selective therapeutic targeting will demarcate the critical trajectory propelling DBD management from rudi- mentary biological comprehension to an era of clinical pre- cision medicine. Funding and conflict of interest This work funded by Yunnan Provin- cial International Joint Research Center for Key Technologies in Uro- logical Diagnosis and Treatment to Kewei Fang with Grant number 202403AP140016 and by Yunnan Province Zhang Yaoguang Expert Workstation to Kewei Fang with Grant number 202405AF140058 and Yunnan Province “Xingdian Talent Program” for Medical and Health Professionals to Kewei Fang with Grant number XDYC-YL- WS-2024-0024.The authors declare that they have no conflict of inter- est. 1 3Acta Diabetologica

  generalfuture work
  Keywords: mitochondrial cellular therapeutic mechanistic yunnan kewei fang grant number remains energetic highly cell largely acta
• Advances in Mitochondrial Dysfunction and Its Role in Cardiovascular Diseases (2025) · Cells · cited 21× · doi

  Mitochondrial dysfunction is a critical factor in CVD pathogenesis as it disrupts ATP production, amplifies oxidative stress, and initiates apoptotic pathways. These disturbances compromise cardiac cellular integrity, exacerbate ischemic injury, and accelerate myocardial remodeling. Recent advances in mitochondria-targeted therapies, including antioxidants, metabolic modulators, and gene-based interventions, offer promising avenues for improv- ing clinical outcomes in CVDs. However, several challenges remain, including the limited therapeutic specificity, off-target effects, and translational barriers. Future research must prioritize three key areas to bridge these gaps: (1) Mechanistic Elucidation: investigating the molecular interplay between mitochondrial dysfunction and CVD progression with a focus on mtDNA integrity, mitophagy regulation, and redox homeostasis. (2) Therapeutic Innovation: The development of precision therapies such as mitochondria-targeted antioxidants (for instance, MitoQ) and modulators of mitochondrial dynamics (such as Drp1 inhibitors) to restore bioenergetic stability. (3) Clinical Translation: Optimizing delivery systems, including nanoparticle carriers, and developing personalized strategies based on metabolic and genetic profiling. Advancing these research priorities will be pivotal in transforming CVD management and transitioning from symptomatic relief to disease-modifying interventions, thereby improving patient survival and quality of life. Despite the significant progress in elucidating the role of mitochondrial dysfunc- tion in CVDs, key knowledge gaps persist, necessitating interdisciplinary efforts to drive translational breakthroughs. Three critical areas warrant immediate attention: (1) System Biology and Precision Medicine: It is imperative to conduct large-scale multi-omics studies that integrate whole-genome sequencing, epigenetics, and single-cell transcriptomics to understand how mitochondrial genetic variants interact with nuclear DNA and environ- mental factors to affect CVD susceptibility. (2) Next-Generation Diagnostics: Cutting-edge platforms combining nanotechnology-based mitochondrial metabolite sensors with artifi- cial intelligence-powered imaging analytics promise to revolutionize CVD diagnosis and monitoring. Real-time, ultra-sensitive assessments of mitochondrial function at single-cell resolution could significantly enhance early disease detection and treatment stratification. (3) Therapeutic Frontiers: Future mitochondria-targeted therapies must surpass conven- tional pharmacology. For instance, the design of next-generation mitochondrial-targeted drugs to selectively modulate respiratory chain function, dynamics, and quality control mechanisms; leveraging CRISPR-derived gene editing for scarless correction of pathogenic mtDNA mutations, creating a foundation for molecular-level CVD therapies; and exploring mitochondrial transplantation and engineered stem cells to restore myocardial bioenergetics and function. However, the path to its clinical translation remains complex. Optimizing mitochondria- targeted delivery systems, establishing standardized diagnostic protocols, and developing regulatory frameworks for novel therapeutics are significant challenges. Simultaneously, Cells 2025, 14, 1621 22 of 36 emerging opportunities lie in synergizing these approaches, such as integrating gene ther- apy with metabolic modulation or combining AI-powered diagnostics with personalized treatment strategies. Addressing these scientific frontiers holds the potential to transition CVD management from symptomatic control to precision mitochondrial medicine, thereby redefining treatment paradigms and improving long-term therapeutic outcomes. Author Contributions: Conceptualization, Y.Z. and X.W.; writing—original draft preparation, Y.Q. and Y.Z.; writing—review and editing, Y.Q., S.C., Y.Z. and X.W.; visualization, Y.Q. and Y.Z.; software, Y.Q. and S.C.; supervision, Y.Z. and X.W.; funding acquisition, X.W. and Y.Z. All authors have read and agreed to the published version of the manuscript. Funding: This research was funded by the Fourteenth Five-Year Plan National Key Speciality Construction Project (Cardiac Macrovascular Surgery), Yunnan Fundamental Research Kunming Medical University Projects (202301AY070001-006), and National Natural Science Foundation of China (No. 12272246). Data Availability Statement: No new data were created or analyzed in this study. Acknowledgments: We thank BioRender (https://www.biorender.com/) for providing the tool to create some figures in this manuscript. Conflicts of Interest: The authors declare no conflicts of interest.

  generalfuture work
  Keywords: mitochondrial targeted mitochondria therapies therapeutic including metabolic gene based clinical precision function treatment dysfunction critical
• Mitochondrial transfer and transplantation in tendon, ligament, and enthesis repair: current evidence, mechanistic rationale, and regenerative opportunities (2026) · Frontiers in Cell and Developmental Biology · doi

  Impaired mitochondrial adaptation can compromise matrix homeostasis, inflammatory resolution, mechanobiological signaling, and repair-cell function. Sustained redox imbalance can damage lipids, proteins, DNA, and mitochondrial membranes. The paper identifies the need for defined donor sources, product identity, indication-specific potency, tissue retention, dosing strategies, safety assessment, disease-relevant models, and functional endpoints.

  generalstated challengesevidence 5/5
  Keywords: impaired mitochondrial adaptation compromise matrix homeostasis inflammatory resolution

Questions about this gap